Mergers & Acquisitions ·
Cumberland Pharmaceuticals Inc. reported Q2 2026 financial results and announced the closing of a strategic…
CPIXCumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. reported Q2 2026 financial results and announced the closing of a strategic transaction with Apotex Health on July 1, 2026. Under the agreement, Apotex acquired Cumberland’s portfolio of FDA-approved brands for $100 million in cash plus $11 million for inventory and transition services. Following this divestiture, Cumberland is transitioning to a development-stage biopharmaceutical organization focused on rare diseases. The company declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026. For the quarter ended June 30, 2026, Cumberland reported a net loss of $4.1 million, including a $3.1 million loss from continuing operations and $1.0 million from discontinued operations. At quarter-end, the company held approximately $4 million in cash and total assets of $62.9 million. Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing late-stage clinical candidates for rare diseases.